Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy.

Kang PB, Lidov HG, White AJ, Mitchell M, Balasubramanian A, Estrella E, Bennett RR, Darras BT, Shapiro FD, Bambach BJ, Kurtzberg J, Gussoni E, Kunkel LM.

Muscle Nerve. 2010 Jun;41(6):746-50. doi: 10.1002/mus.21702.

2.

[Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].

Zhang C, Feng HY, Huang SL, Fang JP, Xiao LL, Yao XL, Chen C, Ye X, Zeng Y, Lu XL, Wen JM, Zhang WX, Li Z, Feng SW, Xu HG, Huang K, Zhou DH, Chen W, Xie YM, Xi J, Zhang M, Li Y, Liu Y.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005 Aug;22(4):399-405. Chinese.

PMID:
16086277
3.

A new immuno-, dystrophin-deficient model, the NSG-mdx(4Cv) mouse, provides evidence for functional improvement following allogeneic satellite cell transplantation.

Arpke RW, Darabi R, Mader TL, Zhang Y, Toyama A, Lonetree CL, Nash N, Lowe DA, Perlingeiro RC, Kyba M.

Stem Cells. 2013 Aug;31(8):1611-20. doi: 10.1002/stem.1402.

4.

Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs.

Dell'Agnola C, Wang Z, Storb R, Tapscott SJ, Kuhr CS, Hauschka SD, Lee RS, Sale GE, Zellmer E, Gisburne S, Bogan J, Kornegay JN, Cooper BJ, Gooley TA, Little MT.

Blood. 2004 Dec 15;104(13):4311-8. Epub 2004 Aug 24.

5.

Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Duchenne Muscular Dystrophy: Safety and Feasibility Study in India.

Rajput BS, Chakrabarti SK, Dongare VS, Ramirez CM, Deb KD.

J Stem Cells. 2015;10(2):141-56.

PMID:
27125141
6.

Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.

Seger RA, Gungor T, Belohradsky BH, Blanche S, Bordigoni P, Di Bartolomeo P, Flood T, Landais P, Müller S, Ozsahin H, Passwell JH, Porta F, Slavin S, Wulffraat N, Zintl F, Nagler A, Cant A, Fischer A.

Blood. 2002 Dec 15;100(13):4344-50. Epub 2002 Aug 8. Review.

7.

Duchenne muscular dystrophy in a female patient with a karyotype of 46,X,i(X)(q10).

Ou Z, Li S, Li Q, Chen X, Liu W, Sun X.

Tohoku J Exp Med. 2010 Oct;222(2):149-53.

8.

[Treatment progress of Duchenne Muscular Dystrophy (DMD)].

Smogorzewska EM, Weinberg KI.

Med Wieku Rozwoj. 2004 Jan-Mar;8(1):25-32. Review. Polish.

PMID:
15557694
9.

[Allogeneic umbilical cord blood stem cell transplantation in Duchenne muscular dystrophy].

Zhang C, Chen W, Xiao LL, Tan EX, Luo SK, Zheng D, Ye X, Li Z, Lu XL, Liu Y.

Zhonghua Yi Xue Za Zhi. 2005 Mar 2;85(8):522-5. Chinese.

PMID:
15949330
10.

Hematopoietic cell transplantation provides an immune-tolerant platform for myoblast transplantation in dystrophic dogs.

Parker MH, Kuhr C, Tapscott SJ, Storb R.

Mol Ther. 2008 Jul;16(7):1340-6. doi: 10.1038/mt.2008.102. Epub 2008 May 27.

11.

Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation.

Gussoni E, Bennett RR, Muskiewicz KR, Meyerrose T, Nolta JA, Gilgoff I, Stein J, Chan YM, Lidov HG, Bönnemann CG, Von Moers A, Morris GE, Den Dunnen JT, Chamberlain JS, Kunkel LM, Weinberg K.

J Clin Invest. 2002 Sep;110(6):807-14.

12.

A new model mouse for Duchenne muscular dystrophy produced by 2.4 Mb deletion of dystrophin gene using Cre-loxP recombination system.

Kudoh H, Ikeda H, Kakitani M, Ueda A, Hayasaka M, Tomizuka K, Hanaoka K.

Biochem Biophys Res Commun. 2005 Mar 11;328(2):507-16.

PMID:
15694376
13.

A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.

Young CS, Hicks MR, Ermolova NV, Nakano H, Jan M, Younesi S, Karumbayaram S, Kumagai-Cresse C, Wang D, Zack JA, Kohn DB, Nakano A, Nelson SF, Miceli MC, Spencer MJ, Pyle AD.

Cell Stem Cell. 2016 Apr 7;18(4):533-40. doi: 10.1016/j.stem.2016.01.021. Epub 2016 Feb 11.

14.

A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.

Li S, Kimura E, Ng R, Fall BM, Meuse L, Reyes M, Faulkner JA, Chamberlain JS.

Hum Mol Genet. 2006 May 15;15(10):1610-22. Epub 2006 Apr 4.

PMID:
16595609
15.

[From gene to disease; the dystrophin gene involved in Duchenne and Becker muscular dystrophy].

den Dunnen JT, de Visser M, Bakker E.

Ned Tijdschr Geneeskd. 2002 Feb 23;146(8):364-7. Review. Dutch.

PMID:
11887623
16.

Tandem duplications of two separate fragments of the dystrophin gene in a patient with Duchenne muscular dystrophy.

Zhang Z, Takeshima Y, Awano H, Nishiyama A, Okizuka Y, Yagi M, Matsuo M.

J Hum Genet. 2008;53(3):215-9. Epub 2007 Dec 27.

PMID:
18160999
17.

Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.

Church JE, Trieu J, Chee A, Naim T, Gehrig SM, Lamon S, Angelini C, Russell AP, Lynch GS.

Exp Physiol. 2014 Apr;99(4):675-87. doi: 10.1113/expphysiol.2013.077255. Epub 2014 Jan 17.

18.

Deletion mutations in the dystrophin gene of Saudi patients with Duchenne and Becker muscular dystrophy.

Al-Jumah M, Majumdar R, Al-Rajeh S, Chaves-Carballo E, Salih MM, Awada A, Al-Shahwan S, Al-Uthaim S.

Saudi Med J. 2002 Dec;23(12):1478-82.

PMID:
12518196
19.

Duchenne and Becker muscular dystrophy: a molecular and immunohistochemical approach.

Freund AA, Scola RH, Arndt RC, Lorenzoni PJ, Kay CK, Werneck LC.

Arq Neuropsiquiatr. 2007 Mar;65(1):73-6.

20.

Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle.

Klymiuk N, Blutke A, Graf A, Krause S, Burkhardt K, Wuensch A, Krebs S, Kessler B, Zakhartchenko V, Kurome M, Kemter E, Nagashima H, Schoser B, Herbach N, Blum H, Wanke R, Aartsma-Rus A, Thirion C, Lochmüller H, Walter MC, Wolf E.

Hum Mol Genet. 2013 Nov 1;22(21):4368-82. doi: 10.1093/hmg/ddt287. Epub 2013 Jun 19.

PMID:
23784375

Supplemental Content

Support Center